Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Biphenotypic, Acute 1

Interventions

Filgrastim 9Cytarabine 9fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 6Whole-Body Irradiation 5Granulocyte Colony-Stimulating Factor 5Cladribine 5Mitoxantrone 4Methotrexate 4Cyclophosphamide 4Melphalan 3Injections 3Cyclosporine 3Biopsy 3venetoclax 2revumenib 2pegylated granulocyte colony-stimulating factor 2X-Rays 2Trimethoprim, Sulfamethoxazole Drug Combination 2Tacrolimus 2Specimen Handling 2Idarubicin 2Decitabine 2Daunorubicin 2Clofarabine 2Busulfan 2Bone Marrow Transplantation 2quizartinib 1merphos 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Biphenotypic, Acute × Acyclovir × Clear all
NCT00061945 2022-05-03

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
302 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡